Synthetic Biologics Inc. (SYN)
-NYSE MKT | Prev Close: | 1.42 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.22 |
|---|
| Beta: | 1.15 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.34 - 2.55 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 60,411 |
|---|
| Market Cap: | 62.99M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.49 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Synthetic Biologics Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 15)
- SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Wed, May 15)
- SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Tue, May 14)
- Genetically Modified Food Investingat Seeking Alpha(Tue, Apr 30)
- SYNTHETIC BIOLOGICS, INC. FinancialsEDGAR Online Financials(Sat, Apr 20)
- Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in EffectPR Newswire(Fri, Apr 19)
- SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Termination of a Material Definitive AgreementEDGAR Online(Fri, Apr 19)
- Synthetic Biologics Reports Year End 2012 Financial ResultsPR Newswire(Tue, Apr 16)
- SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Tue, Apr 16)
- Synthetic Biologics Announces Issuance of U.S. Patent Covering Combination of Estriol and Copaxone® for Multiple SclerosisPR Newswire(Thu, Apr 4)
- Synthetic Biologics to Present at the 25th Annual ROTH ConferencePR Newswire(Tue, Mar 12)
- Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory BoardPR Newswire(Tue, Feb 26)
- Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.PR Newswire(Fri, Feb 22)
- SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Mon, Feb 11)
- 3 Biotech Stocks Under $5 Moving Higherat TheStreet(Thu, Feb 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | N/A |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Synthetics Biologics, Inc., a biotechnology company, focuses on the development of biologics for the prevention and treatment of serious infectious diseases.
View More 
0.80%